Serotonin Syndrome Caused by Selective Serotonin Reuptake-Inhibitors—Metoclopramide Interaction

2002 ◽  
Vol 36 (1) ◽  
pp. 67-71 ◽  
Author(s):  
Alexander A Fisher ◽  
Michael W Davis
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Syndrome ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin

Ssri-related toxic serotonin syndrome: improvement by discontinuation of treatment and propranolol

1997 ◽  
Vol 12 (6) ◽  
pp. 321-323 ◽  
Author(s):  
SM Dursun ◽  
JG Burke ◽  
F Nielsen ◽  
A Mlynik-Szmid ◽  
MA Reveley
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Syndrome ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Discontinuation Of Treatment ◽  
Propranolol Treatment

SummaryWe report three cases in which toxic serotonin syndrome developed in relation to three different selective serotonin reuptake inhibitors (SSRI) (ie, fluoxetine, sertraline, paroxetine), and which all responded to the discontinuation of the SSRI and also to an additional propranolol treatment.

Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors

2013 ◽  
Vol 25 (3) ◽  
pp. 193-199 ◽  
Author(s):  
Yuriy Dobry ◽  
Timothy Rice ◽  
Leo Sher
Keyword(s):  
Health Care ◽  
Young Adults ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Syndrome ◽  
Serotonin Reuptake Inhibitors ◽  
Adolescents And Young Adults ◽  
Selective Serotonin ◽  
Regulatory Body ◽  
Pharmacological Interaction

Abstract Background: At present, there are scarce clinical and basic lab data concerning the risk of acute serotonin toxicity from selective serotonin reuptake inhibitors (SSRIs) and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) co-administration. The health care community can strongly benefit from efforts to address the high risks associated with serotonin syndrome from this specific drug combination. Objective: The aim of this work is to review the risk of serotonin syndrome in adolescents and young adults prescribed with SSRIs and are concurrently using ecstasy. Data sources: An electronic search of the major behavioral science bibliographic databases (Pubmed, PsycINFO, Medline) was conducted to retrieve peer-reviewed articles, which detail the clinical characteristics, biological mechanisms and social implications of SSRIs, MDMA, and their potential synergism in causing serotonin syndrome in the pediatric and young adult population. Search terms included “serotonin syndrome”, “ecstasy”, “MDMA”, “pediatric”, and “SSRI”. Additional references were incorporated from the bibliographies of these retrieved articles. Results: MDMA, in combination with the widely-prescribed SSRI antidepressant class, can lead to rapid, synergistic rise of serotonin (5-HT) concentration in the central nervous system, leading to the acute medical emergency known as serotonin syndrome. This review addresses such complication through an exploration of the theoretical mechanisms and clinical manifestations of this life-threatening pharmacological interaction. Conclusion: The increasing incidences of recreational ecstasy use and SSRI pharmacotherapy among multiple psychiatric disorders in the adolescent population have made this an overlooked yet increasingly relevant danger, which poses a threat to public health. This can be curbed through further research, as well as greater health care provision and attention from a regulatory body owing.

Sign in / Sign up

Export Citation Format

Share Document